Theseus Pharmaceuticals, Inc. THRX
Set alert
As of Feb 13, 3:59 PM ET
52-week range unavailable
- Open
- 4.06
- Prev close
- 4.07
- Mkt cap
- 181.28M
- Vol
- 677.69K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.06
- High
- 4.07
- Forward P/E
- -3.79
- Beta
- 3.98
- Short ratio
- 0.82
- Inst. own
- 84.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 14, 2024
- 50-d avg
- 4.02
- 200-d avg
- 4.47
- 1y target
- 5.25
News
2 years ago prnewswire.com
Theseus Pharmaceuticals Announces Closing of Tender Offer
-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- CAMBRIDGE, Mass. , Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or…
2 years ago prnewswire.com
THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
NEW ORLEANS , Jan. 22, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
2 years ago businesswire.com
THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Theseus…
2 years ago zacks.com
Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?
Theseus Pharmaceuticals (THRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2 years ago prnewswire.com
Shareholder Alert: Ademi LLP investigates whether Theseus Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Concentra
MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Theseus (NASDAQ: THRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra.…
2 years ago businesswire.com
THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) to Concentra Biosciences, LLC for between…
2 years ago prnewswire.com
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
CAMBRIDGE, Mass. , Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives…
2 years ago zacks.com
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.
2 years ago prnewswire.com
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
CAMBRIDGE, Mass. , Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.
3 years ago seekingalpha.com
Theseus Pharmaceuticals: Picking Up The Pieces After A Lead Failure
Theseus Pharmaceuticals experienced significant losses after discontinuing its lead program, leaving it with a market cap of half of its current assets. THRX is now focusing on developing a…
3 years ago zacks.com
Down -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)
The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among…
3 years ago prnewswire.com
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024 Nomination of highly selective…
3 years ago zacks.com
New Strong Buy Stocks for July 19th
SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.
3 years ago zacks.com
After Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)
The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among…
3 years ago benzinga.com
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
3 years ago zacks.com
Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study
Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.
3 years ago investorplace.com
Why Is Theseus Pharmaceuticals (THRX) Stock Down 68% Today?
Theseus Pharmaceuticals (NASDAQ: THRX ) stock is falling hard on Friday after the company announced poor results from a Phase 1/2 clinical trial. According to a press release from Theseus…
3 years ago fool.com
Why These 2 Biotech Stocks Made Big Moves Late Thursday
Stock markets kept climbing on Thursday. Acadia stock moved higher as the company expanded a key licensing agreement.
3 years ago marketwatch.com
Theseus Pharmaceuticals stock plummets after cancer drug development stopped
Theseus Pharmaceuticals Inc. THRX, -3.74% shares plummeted after hours Thursday after the biotech drug maker discontinued enrolling patients in the study of a cancer drug it no longer intend to…
3 years ago prnewswire.com
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR…
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
-
3 years ago benzinga.com
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
-
3 years ago benzinga.com
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 422 stocks made new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows.
-
4 years ago benzinga.com
58 Biggest Movers From Friday
Gainers BEST Inc. (NYSE: BEST) shares gained 73.6% to close at $1.00. DiDi Global Inc. (NYSE: DIDI) shares jumped 59.8% to settle at $4.09 on Friday.
-
15 years ago benzinga.com
Twelve Health Care ETFs Trading Near 52-Week Highs
Twelve Health Care ETFs Trading Near 52-Week Highs